InsidersTradesSigma
Follow the ZEVRA THERAPEUTICS INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €697.2m. The latest transaction was disclosed on 14 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: RAHSAAN THOMPSON. The full history is openly available.
Analysts rate ZEVRA THERAPEUTICS INC Strong Buy (bullish), based on 9 analysts. Average price target: US$25.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Zevra Therapeutics Inc is a company focused on developing treatments for rare and complex diseases. It is listed on the XNAS market.